about project
BRIGHT project evaluates in the European healthcare the implementation of a comprehensive program of genetic risks based personalized breast cancer screening and prevention for women at age 35-49, the age group younger than in current population screening.
For genetic risks prediction the project uses polygenic risk score and monogenic pathogenic variants testing to assess their feasibility with following diagnostic screening and prevention activities. The study will investigate the efficacy, cost-efficiency, feasibility, acceptability, and healthcare system readiness of this approach.
